{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T12:26:15Z","timestamp":1770467175371,"version":"3.49.0"},"reference-count":13,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>Visceral leishmaniasis (VL) is a severe and potentially fatal infection, with over 90% of reported cases occurring in East African countries including Chad, Djibouti, Eritrea, Ethiopia, Kenya, Somalia, South Sudan, Sudan, and Uganda, affecting mainly impoverished individuals, and creating a significant economic burden. Currently, the intravenous single-dose liposomal amphotericin B is the first choice for the treatment of VL. Recently, WHO and DNDi have suggested a combination of intravenous liposomal amphotericin B and oral miltefosine as a potential approach to treat VL. However, miltefosine availability is uncertain, and its side effects frequently cause treatment to be discontinued. Furthermore, due to the difficult route of liposomal amphotericin B administration by intravenous infusion, the lack of formulation\u2019s tropical stability, accessibility, injection toxicity, and cost have prevented this injectable formulation of amphotericin B from reaching the most infected populations, particularly the pediatric population. To solve this problem, the development of a solid oral amphotericin B formulation that is cost-effective, safe, tropically stable, and easy to swallow, making it more accessible to children, particularly in rural communities having limited access to medical clinics or trained healthcare professionals is imperative. This viewpoint will discuss the opportunities and challenges of developing an oral amphotericin B formulation for a pediatric population.<\/jats:p>","DOI":"10.1371\/journal.pntd.0012500","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T17:21:24Z","timestamp":1727371284000},"page":"e0012500","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Development and deployment of a solid oral amphotericin B dosage form to treat visceral leishmaniasis within a pediatric population"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7973-2786","authenticated-orcid":true,"given":"Kishor M.","family":"Wasan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"key":"pntd.0012500.ref001","volume-title":"The World Versus Leishmaniasis","author":"F. Alves","year":"2022"},{"issue":"5","key":"pntd.0012500.ref002","article-title":"Old World Cutaneous Leishmaniasis and Refugee Crises in the Middle East and North Africa","volume":"10","author":"R Du","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0012500.ref003","unstructured":"World Health Organization. Leishmaniasis. 2024. Available from: https:\/\/www.who.int\/health-topics\/leishmaniasis#tab=tab_1."},{"key":"pntd.0012500.ref004","article-title":"Drug Criteria & Outcomes: Lipid-based amphotericin B products formulary evaluation","author":"B. Gilchrist","year":"2002","journal-title":"Drug Formulary Review Archives"},{"issue":"14","key":"pntd.0012500.ref005","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2174\/1381612826666200311130812","article-title":"Development of an Oral Amphotericin B Formulation as an Alternative Approach to Parenteral Amphotericin B Administration in the Treatment of Blood-Borne Fungal Infections","volume":"26","author":"KM Wasan","year":"2020","journal-title":"Curr Pharm Des"},{"issue":"2","key":"pntd.0012500.ref006","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/jof6020066","article-title":"Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached?","volume":"6","author":"M Aigner","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"pntd.0012500.ref007","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/600105","article-title":"Highly effective oral amphotericin B formulation against murine visceral Leishmaniasis","volume":"200","author":"KM Wasan","year":"2009","journal-title":"J Infect Dis"},{"key":"pntd.0012500.ref008","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1476-511X-10-135","article-title":"Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): Biodistribution and toxicity in a mouse model","volume":"10","author":"O Sivak","year":"2011","journal-title":"Lipids Health Dis"},{"key":"pntd.0012500.ref009","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1371\/journal.pntd.0000913","article-title":"A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model","volume":"12","author":"EK Wasan","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0012500.ref010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/1476-511X-12-158","article-title":"Efficacy of an oral and tropically stable lipid-based formulation of Amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasis","volume":"12","author":"F Ibrahim","year":"2013","journal-title":"Lipids Health Dis"},{"issue":"10","key":"pntd.0012500.ref011","doi-asserted-by":"crossref","first-page":"e01450","DOI":"10.1128\/AAC.01450-20","article-title":"Safety, Tolerability, and Pharmacokinetics of a Novel Oral Amphotericin B Formulation (iCo-019) following Single-Dose Administration to Healthy Human Subjects: an Alternative Approach to Parenteral Amphotericin B Administration","volume":"64","author":"P Hnik","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"pntd.0012500.ref012","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4269\/ajtmh.2011.10-0321","article-title":"Who is a typical patient with visceral leishmaniasis? Characterizing the demographic and nutritional profile of patients in Brazil, East Africa, and South Asia","volume":"84","author":"MO Harhay","year":"2011","journal-title":"Am J Trop Med Hyg"},{"issue":"11","key":"pntd.0012500.ref013","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.3390\/pharmaceutics14112316","article-title":"Review of Novel Oral Amphotericin B Formulations for the Treatment of Parasitic Infections","volume":"14","author":"E Wasan","year":"2022","journal-title":"Pharmaceutics"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0012500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T17:21:29Z","timestamp":1727371289000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0012500"}},"subtitle":[],"editor":[{"given":"Shyam","family":"Sundar","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":13,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0012500","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,26]]}}}